Flame retardants (EHC 209, 1998)

INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY

ENVIRONMENTAL HEALTH CRITERIA 209

FLAME RETARDANTS: TRIS(CHLOROPROPYL)
PHOSPHATE AND TRIS(2-CHLOROETHYL)
PHOSPHATE

This report contains the collective views of an international group of
experts and does not necessarily represent the decisions or the stated
policy of the United Nations Environment Programme, the International
Labour Organisation, or the World Health Organization.

Published under the joint sponsorship of the United Nations
Environment Programme, the International Labour Organisation, and the
World Health Organization, and produced within the framework of the
Inter-Organization Programme for the Sound Management of Chemicals.

World Health Organization
Geneva, 1998

The International Programme on Chemical Safety (IPCS),
established in 1980, is a joint venture of the United Nations
Environment Programme (UNEP), the International Labour Organisation
(ILO), and the World Health Organization (WHO). The overall
objectives of the IPCS are to establish the scientific basis for
assessment of the risk to human health and the environment from
exposure to chemicals, through international peer review processes, as
a prerequisite for the promotion of chemical safety, and to provide
technical assistance in strengthening national capacities for the
sound management of chemicals.

The Inter-Organization Programme for the Sound Management of
Chemicals (IOMC) was established in 1995 by UNEP, ILO, the Food and
Agriculture Organization of the United Nations, WHO, the United
Nations Industrial Development Organization, the United Nations
Institute for Training and Research, and the Organisation for Economic
Co-operation and Development (Participating Organizations), following
recommendations made by the 1992 UN Conference on Environment and
Development to strengthen cooperation and increase coordination in the
field of chemical safety. The purpose of the IOMC is to promote
coordination of the policies and activities pursued by the
Participating Organizations, jointly or separately, to achieve the
sound management of chemicals in relation to human health and the
environment.

WHO Library Cataloguing in Publication Data

Flame retardants : tris(chloropropyl) phosphate and
tris(2-chloroethyl) phosphate.

(Environmental health criteria ; 209)

1.Phosphoric acid esters - toxicity
2.Phosphoric acid esters - adverse effects
3.Flame retardants - toxicity
4.Flame retardants - adverse effects
5.Environmental exposure
I.International Programme on Chemical Safety
II.Series

ISBN 92 4 157209 4 (NLM Classification: QD 181.P1)
ISSN 0250-863X

The World Health Organization welcomes requests for permission to
reproduce or translate its publications, in part or in full.
Applications and enquiries should be addressed to the Office of
Publications, World Health Organization, Geneva, Switzerland, which
will be glad to provide the latest information on any changes made to
the text, plans for new editions, and reprints and translations
already available.

Publications of the World Health Organization enjoy copyright
protection in accordance with the provisions of Protocol 2 of the
Universal Copyright Convention. All rights reserved.

The designations employed and the presentation of the material in
this publication do not imply the expression of any opinion whatsoever
on the part of the Secretariat of the World Health Organization
concerning the legal status of any country, territory, city, or area
or of its authorities, or concerning the delimitation of its frontiers
or boundaries.

The mention of specific companies or of certain manufacturers'
products does not imply that they are endorsed or recommended by the
World Health Organization in preference to others of a similar nature
that are not mentioned. Errors and omissions excepted, the names of
proprietary products are distinguished by initial capital letters.

CONTENTS

ENVIRONMENTAL HEALTH CRITERIA FOR FLAME RETARDANTS: TRIS(CHLOROPROPYL)
PHOSPHATE AND TRIS(2-CHLOROETHYL) PHOSPHATE

PREAMBLE

ABBREVIATIONS

TRIS(CHLOROPROPYL) PHOSPHATE

1. SUMMARY

1.1. Tris(1-chloro-2-propyl) phosphate (TCPP)
1.2. Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)

2. IDENTITY, PHYSICAL AND CHEMICAL PROPERTIES, AND ANALYTICAL
METHODS

2.1. Tris(1-chloro-2-propyl) phosphate (TCPP)
2.1.1. Identity
2.1.2. Physical and chemical properties
2.2. Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)
2.2.1. Identity
2.2.2. Physical and chemical properties
2.3. Conversion factors
2.4. Analytical methods

3. SOURCES OF HUMAN AND ENVIRONMENTAL EXPOSURE

3.1. Natural occurrence
3.2. Anthropogenic sources
3.2.1. Production and processes
3.2.2. Release in the environment
3.2.3. Uses
3.2.3.1 TCPP
3.2.3.2 TDCPP

4. ENVIRONMENTAL TRANSPORT, DISTRIBUTION AND TRANSFORMATION

4.1. Transport and distribution between media
4.2. Transformation
4.2.1. Abiotic
4.2.2. Biotic
4.2.3. Degradation
4.2.4. Bioaccumulation

5. ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE

5.1. Environmental levels
5.1.1. Air
5.1.2. Water
5.1.3. Sediment
5.1.4. Biota
5.1.5. Food
5.2. General population exposure
5.2.1. Adipose tissue
5.2.2. Biological fluids

6. KINETICS AND METABOLISM IN LABORATORY ANIMALS

6.1. TCPP
6.2. TDCPP

7. EFFECTS ON LABORATORY MAMMALS AND IN VITRO TEST SYSTEMS

7.1. Single exposure
7.1.1. TCPP
7.1.2. TDCPP
7.2. Short-term exposure
7.2.1. TCPP
7.2.2. TDCPP
7.3. Long-term exposure
7.3.1. TCPP
7.3.2. TDCPP
7.4. Skin and eye irritation or sensitization
7.4.1. TCPP
7.4.1.1 Skin irritation
7.4.1.2 Eye irritation
7.4.1.3 Sensitization
7.4.2. TDCPP
7.4.2.1 Skin irritation
7.4.2.2 Eye irritation
7.4.2.3 Sensitization
7.5. Reproductive toxicity, embryotoxicity and teratogenicity
7.5.1. TCPP
7.5.2. TDCPP
7.6. Mutagenicity and related end-points
7.6.1. TCPP
7.6.2. TDCPP
7.7. Carcinogenicity
7.7.1. TCPP
7.7.2. TDCPP
7.8. Other studies
7.8.1. Immunotoxicity
7.8.1.1 TCPP
7.8.1.2 TDCPP
7.8.2. Neurotoxicity
7.8.2.1 TCPP
7.8.2.2 TDCPP

8. EFFECTS ON HUMANS

8.1. TCPP
8.2. TDCPP

9. EFFECTS ON OTHER ORGANISMS IN THE LABORATORY AND FIELD

9.1. Microorganisms
9.2. Aquatic organisms
9.2.1. Algae
9.2.2. Invertebrates
9.2.3. Fish
9.3. Terrestrial organisms

10. EVALUATION

10.1. TCPP
10.2. TDCPP

11. FURTHER RESEARCH

TRIS(2-CHLOROETHYL) PHOSPHATE

A1. SUMMARY

A2. IDENTITY, PHYSICAL AND CHEMICAL PROPERTIES, AND ANALYTICAL
METHODS

A2.1 Identity
A2.2 Physical and chemical properties
A2.3 Conversion factors
A2.4 Analytical methods

A3. SOURCES OF HUMAN AND ENVIRONMENTAL EXPOSURE

A3.1 Natural occurrence
A3.2 Anthropogenic sources
A3.2.1 Production and processes
A3.2.2 Uses

A4. ENVIRONMENTAL TRANSPORT, DISTRIBUTION AND TRANSFORMATION

A4.1 Transport and distribution between media
A4.2 Transformation
A4.2.1 Abiotic
A4.2.2 Biotic
A4.3 Bioaccumulation

A5. ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE

A5.1 Environmental levels
A5.1.1 Air
A5.1.2 Water
A5.1.2.1 Surface water
A5.1.2.2 Drinking-water
A5.1.2.3 Effluents
A5.1.2.4 Leachates
A5.2 Sediment
A5.3 Biota and food
A5.3.1 Biota
A5.3.2 Food

A6. KINETICS AND METABOLISM IN LABORATORY ANIMALS

A6.1 Mice
A6.2 Rats

A7. EFFECTS ON LABORATORY MAMMALS AND IN VITRO TEST SYSTEMS

A7.1 Single exposure
A7.2 Short-term exposure
A7.2.1 Mice
A7.2.2 Rats
A7.3 Long-term exposure
A7.3.1 Mice
A7.3.2 Rats
A7.4 Skin and eye irritation or sensitization
A7.4.1 Skin irritation
A7.4.2 Eye irritation
A7.4.3 Sensitization
A7.5 Reproductive toxicity, embryotoxicity and teratogenicity
A7.5.1 Developmental toxicity
A7.5.2 Fertility
A7.6 Mutagenicity and related end-points
A7.6.1 In vitro studies
A7.6.2 In vivo studies
A7.7 Carcinogenicity
A7.7.1 Oral
A7.7.1.1 Mice
A7.7.1.2 Rats
A7.7.2 Dermal
A7.7.2.1 Mice
A7.8 Other special studies
A7.8.1 Neurotoxicity

A8. EFFECTS ON HUMANS

A9. EFFECTS ON OTHER ORGANISMS IN THE LABORATORY AND FIELD

A9.1 Microorganisms
A9.2 Aquatic organisms
A9.2.1 Algae
A9.2.2 Invertebrates
A9.2.3 Fish

A10. EVALUATION

A11. FURTHER RESEARCH

A12. PREVIOUS EVALUATIONS BY INTERNATIONAL BODIES

REFERENCES

RÉSUMÉ

RESUMEN

NOTE TO READERS OF THE CRITERIA MONOGRAPHS

Every effort has been made to present information in the criteria
monographs as accurately as possible without unduly delaying their
publication. In the interest of all users of the Environmental Health
Criteria monographs, readers are requested to communicate any errors
that may have occurred to the Director of the International Programme
on Chemical Safety, World Health Organization, Geneva, Switzerland, in
order that they may be included in corrigenda.

* * *

A detailed data profile and a legal file can be obtained from the
International Register of Potentially Toxic Chemicals, Case postale
356, 1219 Châtelaine, Geneva, Switzerland (telephone no. + 41 22 -
9799111, fax no. + 41 22 - 7973460, E-mail irptc@unep.ch).

* * *

This publication was made possible by grant number
5 U01 ES02617-15 from the National Institute of Environmental Health
Sciences, National Institutes of Health, USA, and by financial support
from the European Commission.

Environmental Health Criteria

PREAMBLE

Objectives

In 1973 the WHO Environmental Health Criteria Programme was
initiated with the following objectives:

(i) to assess information on the relationship between exposure to
environmental pollutants and human health, and to provide
guidelines for setting exposure limits;

(ii) to identify new or potential pollutants;

(iii) to identify gaps in knowledge concerning the health effects of
pollutants;

(iv) to promote the harmonization of toxicological and epidemio
logical methods in order to have internationally comparable
results.

The first Environmental Health Criteria (EHC) monograph, on
mercury, was published in 1976 and since that time an ever-increasing
number of assessments of chemicals and of physical effects have been
produced. In addition, many EHC monographs have been devoted to
evaluating toxicological methodology, e.g., for genetic, neurotoxic,
teratogenic and nephrotoxic effects. Other publications have been
concerned with epidemiological guidelines, evaluation of short-term
tests for carcinogens, biomarkers, effects on the elderly and so
forth.

Since its inauguration the EHC Programme has widened its scope,
and the importance of environmental effects, in addition to health
effects, has been increasingly emphasized in the total evaluation of
chemicals.

The original impetus for the Programme came from World Health
Assembly resolutions and the recommendations of the 1972 UN Conference
on the Human Environment. Subsequently the work became an integral
part of the International Programme on Chemical Safety (IPCS), a
cooperative programme of UNEP, ILO and WHO. In this manner, with the
strong support of the new partners, the importance of occupational
health and environmental effects was fully recognized. The EHC
monographs have become widely established, used and recognized
throughout the world.

The recommendations of the 1992 UN Conference on Environment and
Development and the subsequent establishment of the Intergovernmental
Forum on Chemical Safety with the priorities for action in the six
programme areas of Chapter 19, Agenda 21, all lend further weight to
the need for EHC assessments of the risks of chemicals.

Scope

The criteria monographs are intended to provide critical reviews
on the effect on human health and the environment of chemicals and of
combinations of chemicals and physical and biological agents. As
such, they include and review studies that are of direct relevance for
the evaluation. However, they do not describe every study carried
out. Worldwide data are used and are quoted from original studies,
not from abstracts or reviews. Both published and unpublished reports
are considered and it is incumbent on the authors to assess all the
articles cited in the references. Preference is always given to
published data. Unpublished data are only used when relevant
published data are absent or when they are pivotal to the risk
assessment. A detailed policy statement is available that describes
the procedures used for unpublished proprietary data so that this
information can be used in the evaluation without compromising its
confidential nature (WHO (1990) Revised Guidelines for the Preparation
of Environmental Health Criteria Monographs. PCS/90.69, Geneva, World
Health Organization).

In the evaluation of human health risks, sound human data,
whenever available, are preferred to animal data. Animal and in
vitro studies provide support and are used mainly to supply evidence
missing from human studies. It is mandatory that research on human
subjects is conducted in full accord with ethical principles,
including the provisions of the Helsinki Declaration.

The EHC monographs are intended to assist national and
international authorities in making risk assessments and subsequent
risk management decisions. They represent a thorough evaluation of
risks and are not, in any sense, recommendations for regulation or
standard setting. These latter are the exclusive purview of national
and regional governments.

Content

The layout of EHC monographs for chemicals is outlined below.

* Summary -- a review of the salient facts and the risk evaluation
of the chemical
* Identity -- physical and chemical properties, analytical methods
* Sources of exposure
* Environmental transport, distribution and transformation
* Environmental levels and human exposure
* Kinetics and metabolism in laboratory animals and humans
* Effects on laboratory mammals and in vitro test systems
* Effects on humans
* Effects on other organisms in the laboratory and field
* Evaluation of human health risks and effects on the environment
* Conclusions and recommendations for protection of human health
and the environment
* Further research

* Previous evaluations by international bodies, e.g., IARC, JECFA,
JMPR

Selection of chemicals

Since the inception of the EHC Programme, the IPCS has organized
meetings of scientists to establish lists of priority chemicals for
subsequent evaluation. Such meetings have been held in: Ispra, Italy,
1980; Oxford, United Kingdom, 1984; Berlin, Germany, 1987; and North
Carolina, USA, 1995. The selection of chemicals has been based on the
following criteria: the existence of scientific evidence that the
substance presents a hazard to human health and/or the environment;
the possible use, persistence, accumulation or degradation of the
substance shows that there may be significant human or environmental
exposure; the size and nature of populations at risk (both human and
other species) and risks for environment; international concern, i.e.
the substance is of major interest to several countries; adequate data
on the hazards are available.

If an EHC monograph is proposed for a chemical not on the
priority list, the IPCS Secretariat consults with the Cooperating
Organizations and all the Participating Institutions before embarking
on the preparation of the monograph.

Procedures

The order of procedures that result in the publication of an EHC
monograph is shown in the flow chart. A designated staff member of
IPCS, responsible for the scientific quality of the document, serves
as Responsible Officer (RO). The IPCS Editor is responsible for
layout and language. The first draft, prepared by consultants or,
more usually, staff from an IPCS Participating Institution, is based
initially on data provided from the International Register of
Potentially Toxic Chemicals, and reference data bases such as Medline
and Toxline.

The draft document, when received by the RO, may require an
initial review by a small panel of experts to determine its scientific
quality and objectivity. Once the RO finds the document acceptable as
a first draft, it is distributed, in its unedited form, to well over
150 EHC contact points throughout the world who are asked to comment
on its completeness and accuracy and, where necessary, provide
additional material. The contact points, usually designated by
governments, may be Participating Institutions, IPCS Focal Points, or
individual scientists known for their particular expertise. Generally
some four months are allowed before the comments are considered by the
RO and author(s). A second draft incorporating comments received and
approved by the Director, IPCS, is then distributed to Task Group
members, who carry out the peer review, at least six weeks before
their meeting.

The Task Group members serve as individual scientists, not as
representatives of any organization, government or industry. Their
function is to evaluate the accuracy, significance and relevance of
the information in the document and to assess the health and
environmental risks from exposure to the chemical. A summary and
recommendations for further research and improved safety aspects are
also required. The composition of the Task Group is dictated by the
range of expertise required for the subject of the meeting and by the
need for a balanced geographical distribution.

The three cooperating organizations of the IPCS recognize the
important role played by nongovernmental organizations.
Representatives from relevant national and international associations
may be invited to join the Task Group as observers. While observers
may provide a valuable contribution to the process, they can only
speak at the invitation of the Chairperson. Observers do not
participate in the final evaluation of the chemical; this is the sole
responsibility of the Task Group members. When the Task Group
considers it to be appropriate, it may meet in camera.

All individuals who as authors, consultants or advisers
participate in the preparation of the EHC monograph must, in addition
to serving in their personal capacity as scientists, inform the RO if
at any time a conflict of interest, whether actual or potential, could
be perceived in their work. They are required to sign a conflict of
interest statement. Such a procedure ensures the transparency and
probity of the process.

When the Task Group has completed its review and the RO is
satisfied as to the scientific correctness and completeness of the
document, it then goes for language editing, reference checking, and
preparation of camera-ready copy. After approval by the Director,
IPCS, the monograph is submitted to the WHO Office of Publications for
printing. At this time a copy of the final draft is sent to the
Chairperson and Rapporteur of the Task Group to check for any errors.

It is accepted that the following criteria should initiate the
updating of an EHC monograph: new data are available that would
substantially change the evaluation; there is public concern for
health or environmental effects of the agent because of greater
exposure; an appreciable time period has elapsed since the last
evaluation.

All Participating Institutions are informed, through the EHC
progress report, of the authors and institutions proposed for the
drafting of the documents. A comprehensive file of all comments
received on drafts of each EHC monograph is maintained and is
available on request. The Chairpersons of Task Groups are briefed
before each meeting on their role and responsibility in ensuring that
these rules are followed.

WHO TASK GROUP ON ENVIRONMENTAL HEALTH CRITERIA FOR FLAME RETARDANTS:
TRIS(CHLOROPROPYL) PHOSPHATE AND TRIS(2-CHLOROETHYL) PHOSPHATE

Members

Dr R. Benson, US Environmental Protection Agency, Denver, Colorado,
USA (Rapporteur)

Mr R. Cary, Health and Safety Executive, Toxicology Unit, Bootle,
Merseyside, United Kingdom

Dr S. Dobson, Institute of Terrestrial Ecology, Monks Wood,
Huntingdon, Cambridgeshire, United Kingdom

Mr D. Renshaw, Department of Health, London, United Kingdom
(Chairman)

Dr E. Söderlund, National Institute of Public Health, Department of
Environmental Medicine, Oslo, Norway

Dr J. Wagstaff, US Food and Drug Administration, Center for Food
Safety and Applied Nutrition, Washington, DC, USA

Observers

Dr R. Henrich, AKZO NOBEL, Dobbs Ferry, New York, USA

Dr P. Martin, Albright and Wilson UK Limited, European Business
Services - Product Stewardship, Oldbury, West Midlands, United Kingdom

Mr M. Papez, European Flame Retardants Association (EFRA), c/o
European Chemical Industry Council (CEFIC), Brussels, Belgium

Mr D. Thornton, Courtaulds Chemicals, Spondon, Derby, United Kingdom

Secretariat

Dr M. Baril, International Programme on Chemical Safety, Montreal,
Quebec, Canada (Secretary)

Dr P.G. Jenkins, International Programme on Chemical Safety, World
Health Organization, Geneva, Switzerland

ENVIRONMENTAL HEALTH CRITERIA FOR FLAME RETARDANTS: TRIS(CHLOROPROPYL)
PHOSPHATE AND TRIS(2-CHLOROETHYL) PHOSPHATE

A WHO Task Group on Environmental Health Criteria for Flame
Retardants: Tris(chloropropyl) phosphate and Tris(2-chloroethyl)
phosphate met at the offices of the Health and Safety Executive (HSE),
London, United Kingdom from 9 to 13 March 1998. Drs B. Woodard (HSE)
and P. Brantom (British Industrial Biological Research Association)
opened the meeting and welcomed the participants on behalf of the
organizing institutes. Dr M. Baril, IPCS, welcomed the participants on
behalf of Dr M. Mercier, Director of the IPCS and the three
cooperating organizations (UNEP/ILO/WHO). The Task Group reviewed and
revised the draft monograph and made an evaluation of the risk to
human health and the environment from exposure to these flame
retardants.

Financial support for this Task Group was provided by the United
Kingdom Department of Health as part of its contribution to the IPCS.

The first draft of this monograph was prepared by Dr G. J. van
Esch, Bilthoven, the Netherlands. The second draft, prepared by Dr M.
Baril, incorporated the comments received following circulation of the
first draft to the IPCS contact points for Environmental Health
Criteria monographs.

Dr P.G. Jenkins (IPCS Central Unit, Geneva) and Dr M. Baril (IPCS
technical adviser, Montreal) were responsible for the overall
technical editing and scientific content, respectively.

The efforts of all who helped in the preparation and finalization
of the monograph are gratefully acknowledged.

* * *

ABBREVIATIONS

BaP benzo (a)pyrene
BCF bioconcentration factor
CA chromosome aberration
ECD electron capture detection
FPD flame photometric detection
GC gas chromatography
ip intraperitoneal
LOEC lowest-observed-effect concentration
LOEL lowest-observed-effect level
MS mass spectrometry
NADPH reduced nicotinamide adenine dinucleotide phosphate
NCI negative ion chemical ionization
ND not detectable
NOEC no-observed-effect concentration
NOEL no-observed-effect level
NPD nitrogen phosphorus detection
NTE neurotoxic esterase
OECD Organisation for Economic Co-operation and Development
PB phenobarbital
PCB polychlorinated biphenyl
SC subcutaneous
SCE sister chromatid exchange
TCEP tris(2-chloroethyl) phosphate
TCPP tris(1-chloro-2-propyl) phosphate
TDCPP tris(1,3-dichloro-2-propyl) phosphate
TOCP tris- ortho-cresyl phosphate

TRIS(CHLOROPROPYL) PHOSPHATE

Tris(1-chloro-2-propyl) phosphate
Tris(1,3-dichloro-2-propyl) phosphate

1. SUMMARY

1.1 Tris(1-chloro-2-propyl) phosphate (TCPP)

Tris(1-chloro-2-propyl) phosphate (TCPP) is a colourless liquid
used as a flame retardant, mainly in polyurethane foams. It is not
volatile. Its solubility in water is 1.6 g/litre, it is soluble in
most organic solvents, and it has a log octanol/water partition
coefficient of 2.59.

Analysis is by gas chromatography/mass spectrometry (GC/MS).
Concentration of TCPP from water prior to analysis can be achieved
using XAD resin, followed by extraction with various organic solvents.

TCPP is manufactured from propylene oxide and phosphorus
oxychloride. Annual worldwide demand exceeded 40 000 tonnes in 1997.

TCPP is not readily biodegraded in sewage sludge inocula. It is
rapidly metabolized in fish.

Traces of TCPP have been detected in industrial and domestic
effluents but not in surface waters. It has not been detected in
surveys of sediments. Traces of TCPP have been detected in raw
peaches, raw pears and fish.

No data are available on the kinetics and metabolism of TCPP in
mammals.

TCPP is of low to moderate acute toxicity by the oral (LD₅₀ in
rats = 1017-4200 mg/kg body weight), dermal (LD₅₀ in rats and rabbits
is > 5000 mg/kg body weight) and inhalation routes (LC₅₀ in rats is
> 4.6 mg/litre).

Rabbit eye and skin irritancy studies have indicated that TCPP is
either non-irritant or mildly irritant. A skin sensitization study
showed that TCPP has no sensitizing properties.

The reproductive toxicity, immunotoxicity and carcinogenic
potential of TCPP have not been investigated. The results of in
vitro and in vivo mutagenicity studies investigating an
appropriate range of end-points indicate that TCPP is not genotoxic.

TCPP has been investigated for potential delayed neurotoxicity in
hens. There was no evidence of delayed neurotoxicity when two oral
doses (each of 13 230 mg/kg body weight) were given 3 weeks apart.

No studies of the effects of TCPP on humans are available.

Toxicity values for organisms in the environment are available,
LC₅₀ values ranging from 3.6 to 180 mg/litre. The no-observed-effect
concentrations for algae, daphnids and fish are 6, 32 and 9.8
mg/litre, respectively.

1.2 Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)

Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) is a viscous
colourless liquid used as a flame retardant in a range of plastic
foams, resins and latexes. It is not volatile. Its solubility in water
is 0.1 g/litre, it is soluble in most organic solvents, and it has a
log octanol/water partition coefficient of 3.8.

Analysis is by GC/MS. Concentration of TDCPP from water prior to
analysis can be achieved using XAD resin, followed by extraction with
various organic solvents.

TDCPP is manufactured from epichlorohydrin and phosphorus
oxychloride. The commercial product is predominantly TDCPP with trace
amounts of tris (2,3-dichloropropyl) phosphate. Annual worldwide
demand was 8000 tonnes in 1997.

TDCPP is not readily degraded in sewage sludge inocula.

Studies have demonstrated limited degradation of TDCPP in natural
waters. It is rapidly metabolized by fish.

Bioconcentration factors are low (3-107). The half-life of
elimination in killifish is 1.65 h.

Traces of TDCPP have been detected in sewage effluent, river
water, seawater, drinking-water, sediment and in fish. TDCPP has been
found in some samples of human adipose tissue.

Kinetic studies in rats using ¹⁴C-labelled TDCPP showed the
radiolabel to be distributed throughout the body following oral or
dermal administration. The major metabolite of TDCPP identified in the
urine of rats was bis(1,3-dichloro-2-propyl) phosphate. Elimination of
the radiolabel was primarily in faeces and urine, with a small amount
in expired air as CO₂.

TDCPP is of low to moderate acute toxicity by the oral route
(LD₅₀ in rats = 2830 mg/kg body weight) and of low acute toxicity by
the dermal route (dermal LD₅₀ in rats is > 2000 mg/kg body weight).

In a 3-month study in mice, an exposure of approximately 1800
mg/kg body weight per day caused death within one month. The
no-observed-effect level (NOEL) for the study was 15.3 mg/kg body
weight per day; the lowest-observed level (LOEL) for increased liver
weight was 62 mg/kg body weight per day.

The sensitization potential of TDCPP has not been investigated.

The potential for TDCPP to affect human male reproductive ability
is unclear in view of testicular toxicity in rats but a lack of effect
on male reproductive performance in rabbits. The possible effect on
female reproduction has not been investigated.

A teratology study on rats showed fetotoxicity at an oral dose of
400 mg/kg body weight per day; there was maternal toxicity at doses of
100 and 400 mg/kg body weight per day. No teratogenicity was seen.

Overall, the mutagenicity data show that TDCPP is not genotoxic
in vivo.

The carcinogenicity of TDCPP has been investigated in a single
2-year feeding study. It was carcinogenic (increased occurrence of
liver carcinomas) at all exposure levels that were tested (5-80 mg/kg
body weight per day) in both male and female rats. Kidney, testicular
and brain tumours were also found. In addition, there were
non-neoplastic adverse effects in bone marrow, spleen, testis, liver
and kidney. The effects in the kidney and testis occurred at all
exposure levels. Only animals in the highest dose and control groups
were evaluated for effects in the bone marrow and spleen. It was
impossible, therefore, to determine whether there was a dose-response
relationship for these effects in these organs.

TDCPP exposure produced some indications of immunotoxicity in
mice but only at high doses.

Limited human studies following occupational exposure are
available but they add little to the knowledge of the safety aspects
of TDCPP.

2. IDENTITY, PHYSICAL AND CHEMICAL PROPERTIES, AND ANALYTICAL METHODS

2.1 Tris(1-chloro-2-propyl) phosphate (TCPP)

2.1.1 Identity

Chemical formula: C₉H₁₈Cl₃O₄P

Chemical structure:

Relative molecular mass: 327.55

CAS name: tris(2-chloroisopropyl) phosphate

CAS registry number: 13674-84-5

Synonyms: 2-propanol, 1-chlorophosphate (3:1);
1-chloro-2-propyl phosphate (1:3);
tris(1-chloromethylethyl) phosphate;
tris(2-chloroisopropyl) phosphate;
tris(ß-chloropropyl) phosphate;
phosphoric acid, tris(2-chloro-1-methyl
ethyl) ester

Trade names: Fyrol PCF; Amgard TMCP; Antiblaze 80;
Levagard PP; Tolgard TMCP; TCPP

Common names: TCPP; TMCP; TCIP

2.1.2 Physical and chemical properties

Physical state: clear, colourless liquid

Melting point: -42°C

Boiling point: 235-248°C

Flash point: 218°C (Cleveland open cup method)

Vapour pressure: <2 mmHg at 25°C

Viscosity: 61 cP at 25°C

Specific gravity: 1.29 at 25°C

Solubility in water: 1.6 g/litre at 20°C

Stability: Hydrolyses slowly under alkaline or acidic
conditions

n-Octanol/water partition
coefficient (log P_ow): 2.59

References: ECB (1995); Akzo (1995)

2.2 Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)

2.2.1 Identity

Chemical formula: C₉H₁₅Cl₆O₄P

Relative molecular mass: 430.91

CAS name: tris(1,3-dichloroisopropyl) phosphate

CAS registry number: 13674-87-8

Synonyms: 1,3-dichloro-2-propanol phosphate;
2-propanol, 1,3-dichloro-, phosphate;
phosphoric acid tris(1,3-dichloro-2- propyl)
ester; tris(1-chloromethyl-2-chloroethyl)
phosphate; tris(1,3-dichloroisopropyl)
phosphate; tris(1,3-dichloro-2-propyl)
phosphate; tris [2-chloro-1-(chloromethyl)
ethyl] phosphate

Trade names: CRP; Firemaster T33P; Fyrol FR 2; PF 38; PF
38/3; Apex Flame Proof Emulsion 197 and 212;
Antiblaze 195; Amgard; TDCP

Common names: TDCPP; TDCP

There is some confusion concerning TDCPP isomers. The commercial
product has predominantly branched substituent propyl groups in the
"iso" orientation joined via the centre carbon. The alternate isomer,
i.e. tris(2,3-dichloro-1-propyl) phosphate (CAS registry number
78-43-3), exists only as a trace in the former because of steric
hindrance from chlorine substitution on adjacent carbon atoms.
Commercial production via reaction of phosphorus oxychloride and
epichlorohydrin can, therefore, only produce the major species:

i.e.

It is therefore assumed that all referenced studies were
conducted on commercial samples (CAS registry number 13674-87-4).

2.2.2 Physical and chemical properties

Physical state: viscous liquid

Boiling point: 236-237°C at 5 mmHg
(decomposes at > 200°C at 4 mmHg)

Specific gravity: 1.52 at 25°C

Solubility: 0.1 g/litre (30°C) in water;
soluble in most organic solvents

Flash point: 252°C (Cleveland open cup method)

Stability: resistant to chlorination in aqueous
solution; it has an extremely low rate of
hydrolysis and resists attack by bases

Viscosity: 1800 cP (25°C)

n-Octanol/water partition
coefficient (log P_ow): 3.8

Vapour pressure: 0.01 mmHg at 30°C

References: Hollifield (1979); Sasaki et al. (1981); Windholz (1983);
Chemical Information Systems (1988); Ishikawa & Baba (1988); Akzo
(1997b)

2.3 Conversion factors

TCPP
1 ppm = 0.0746 mg/m³
1 mg/m³ = 13.39 ppm

TDCPP
1 ppm = 0.0567 mg/m³
1 mg/m³ = 17.62 ppm

2.4 Analytical methods

Gas chromatography and mass spectrometry (GC/MS) with a
nitrogen-phosphorus detector (GC/NPD) is used to detect
tris(chloropropyl) phosphates in drinking-water and adipose tissue.
Water samples are prepared as follows: absorption on a XAD resin
cartridge, extraction with methylene chloride or elution with
acetone/hexane, drying over anhydrous sodium sulfate and concentration
and determination by GC/MS (LeBel et al., 1981; Benoit & LeBel, 1986).
LeBel et al. (1987) used large-volume resin sampling cartridges to
obtain sufficient organic extracts from water for analysis. Recovery
at 10 ng TDCPP/litre fortification was 96.8%.

The limit of determination for tris(chloropropyl) phosphates in
human adipose tissue is < 1 ng/g (LeBel & Williams, 1983). The
recovery of TDCPP from human adipose tissue fortified with TDCPP was
92.1 to 111.4% in a concentration range of 2.5-25 µg/kg with benzene
extraction (LeBel & Williams, 1983).

Gas chromatography with negative chemical ionization mass
spectrometry (GC/NCIMS) has been used to identify TDCPP in human blood
samples (Sellström & Jansson, 1987).

TDCPP can be analysed in food by GC/NPD (Draft, 1982).

3. SOURCES OF HUMAN AND ENVIRONMENTAL EXPOSURE

3.1 Natural occurrence

Neither TCPP nor TDCPP occur as natural products.

3.2 Anthropogenic sources

3.2.1 Production and processes

TCPP production and use has continued to grow at an average of 4%
per year since the mid-1960s when it was first commercialized. Its
growth has been a reflection of polyurethane tonnage growth compounded
by legislative advances and the fact that TCPP has replaced some other
flame retardants, e.g., tris(chloroethyl) phosphate (TCEP).

All commercial TCPP is produced by the reaction of phosphorus
oxychloride with propylene oxide followed by purification.

All commercial TDCPP is produced by reaction of phosphorus
oxychloride with epichlorohydrin.

In 1997, global TCPP demand reached over 40 000 tonnes per year;
global TDCPP demand was estimated at 8000 tonnes per year and growing.

3.2.2 Release in the environment

The environmental fate of TCPP is unknown; entry into and
transport through the aquatic media, however, appear to be the most
likely sources of contamination. TCPP fire retardants could
potentially reach the environment from waste streams generated: (a) in
manufacturing plants; (b) where they are added to fabrics and
plastics; and (c) from the final product during its use, disposal or
recycling. Their transport to the environment could also occur by
atmospheric emissions, by leaching or with the movement of treated
fabrics or plastic products (US EPA, 1976).

Ahrens et al. (1979) determined the rate of release of TDCPP as a
function of the number of launderings of children's polyester
sleepwear. They observed that about 37% of the flame retardant was
lost after 20 washings, most of which was lost by the tenth wash.
Prepolymers containing polyethyleneimine with TDCPP impart flame
retardancy to cotton fabrics but do not withstand persistent
laundering (Bertoniere & Rowland, 1977).

TDCPP may undergo thermal oxidative degradation in air at 370°C.
The major chlorinated C3 species (97% volatiles) are
1,3-dichloropropene and 1,2,3-trichloropropane and acrolein.
Hydrochloric acid is also produced.

3.2.3 Uses

3.2.3.1 TCPP

The vast majority of TCPP is used in rigid polyurethane foams. It
is also used in flexible polyurethane foams for furniture and its
upholstery, principally in the United Kingdom and Ireland.

TCPP is added at various points in the polyurethane supply chain:
to final foam producers; to "system houses" who pre-blend and
formulate ready-made systems; and to base polyol producers who may use
it to reduce polyol viscosity/mobility.

The use in rigid polyurethane foams may be further sub-divided
into blocks and spray systems for building insulation and for
refrigerator casings. Very small use of TCPP also exists in textile
back-coating formulations and in certain coatings.

3.2.3.2 TDCPP

TDCPP is added as a flame retardant to: (a) polyurethane foam
(both rigid and flexible); (b) other plastics and resins; and (c)
acrylic latexes for back coating and binding of non-woven fabrics
(Weil, 1980; US EPA, 1988).

Incorporation of TDCPP into polyurea coatings for application to
wool has produced flame-resistant, machine-washable and
shrink-resistant material (Fincher et al., 1973).

TDCPP was formerly used as a flame retardant for children's and
infant's clothing.

4. ENVIRONMENTAL TRANSPORT, DISTRIBUTION AND TRANSFORMATION

4.1 Transport and distribution between media

No data are available regarding transport and distribution of
TCPP or TDCPP between different media.

4.2 Transformation

4.2.1 Abiotic

TCPP hydrolyses slowly under both acidic and alkaline conditions
(Akzo, 1997a).

4.2.2 Biotic

TCPP is not readily biodegradable in sewage sludge inocula.
Following inoculation at 20 mg/litre in a MITI test, 14% was degraded
in 28 days (MITI, 1992). After inoculation at 100 mg/litre in a test
under OECD Guideline 3OI C, there was no degradation within 28 days
(Bayer AG, 1990, unpublished data). Using Amgard TMCP, TCPP was
assessed for inherent biodegradability under OECD Guideline 302C.
Calculated degradation (from oxygen uptake) was 21% after 28 days
(SafePharm, 1996a). In the same test, Amgard TDCP (TDCPP), showed no
degradation within 28 days (SafePharm, 1996b).

4.2.3 Degradation

Hattori et al. (1981) studied the degradation of TDCPP in
environmental water during 1979-1980. Using the molybdenum blue
colorimetric method, the increase of phosphate ions was analysed in Oh
River and Neya River water and seawater from Osaka Bay. According to
measurements made at 7 and 14 days, the degradation was 12.5 and
18.5%, respectively, when 20 mg TDCPP/litre was added to water from
the Oh River, 0 and 5.4%, respectively, when 1 mg/litre was added to
water from the Neya River, 0 and 22% respectively in seawater from
Osaka Bay (Tomagashima), and 0% in seawater from Osaka Bay (Senboku).

The percentage degradation of TDCPP in water in the presence of
killifish (Orzyias latipes) or goldfish (Carassius auratus) was
monitored by Sasaki et al. (1981). Initial concentration and fish
numbers per unit volume were not reported. More than 90% of the TDCPP
degradation with killifish, and approximately 70% with goldfish,
occurred within 100 h; the half-lives being 31 h for killifish and 42
h for goldfish.

4.2.4 Bioaccumulation

Bioaccumulation of TDCPP was studied in both static and
continuous-flow tests using killifish (Oryzias latipes). In static
tests, bioconcentration factors (BCFs) ranged from 47 to 107 following

exposure to TDCPP at 0.3-1.2 mg/litre for 96 h. In continuous-flow
systems, BCFs ranged from 31 to 59 following exposure to 0.04-0.4
mg/litre over 3 to 32 days. The half-life of elimination was 1.65 h
following transfer to clean water after exposure in the
continuous-flow system (Sasaki et al., 1982). Static BCFs for goldfish
(Carassius auratus) ranged from 3 to 5 for TDCPP (Sasaki et al.,
1981).

5. ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE

5.1 Environmental levels

5.1.1 Air

TCPP and TDCPP concentrations of 0.0053 and 0.0047 µg/m³,
respectively, were measured in the ambient air of Kitakyushu, Japan,
in 1983 (Haraguchi et al., 1985).

5.1.2 Water

In 1975 and 1978 more than 100 samples of river water were
analysed in Japan for the presence of TDCPP. In 1975 0/100 and in 1978
0/114 samples contained the substance. The limit of determination in
1975 was 0.02-0.25 and in 1978 it was 0.001-0.5 µg/litre
(Environmental Agency Japan, 1983, 1987).

In a survey conducted in 1980, 25 samples of river water and
seawater were collected near Kitakyushu City, Japan, and analysed for
TDCPP. All samples contained this phosphate at concentrations of
0.023-0.136 µg/litre (limit of determination, 0.01 µg/litre) (Ishikawa
et al., 1985a).

Twenty-four samples of water were collected and analysed for the
presence of TDCPP in Japan in 1984. None of the samples contained
either TDCPP (limit of determination 0.25-1 µg/litre) or TCPP (limit
of determination 0.05-1 µg/litre) (Environmental Agency Japan, 1987;
personal communication from the Japanese Ministry of Health and
Welfare to the IPCS, July 1993).

TDCPP has been identified in raw river water and drinking-water
extracted from Japanese rivers (Takahashi & Morita, 1988). A study of
river water samples collected at Isojima in the Yodo river basin in
1984 led to the conclusion that urban run-off was not a source of
river water pollution in that area (Fukushima et al., 1986). Fukushima
et al. (1992) determined the trend of TCPP and TDCPP levels in the
basin from 1976 to 1990. There was a peak in the polluted area of
TDCPP in 1987 where the concentration reached 0.9 µg/litre and one in
a less polluted area in 1988 where it was 0.6 µg/litre.

Industrial and domestic effluents in Kitakyushu, Japan, contained
detectable levels of TDCPP (limit of determination, 0.03 µg/litre).
The concentration ranged from not detectable (ND) to 0.1 µg/litre at 3
food factories, ND to 0.6 µg/litre at 7 chemical factories, ND to 0.29
µg/litre at 5 steel factories, ND to 0.59 µg/litre at 6 other
industrial sites and ND to 0.18 µg/litre at 3 metal processing plants,
0.28 to 1.4 µg/litre in 5 sewage treatment plant effluents (influents
0.33 to 1.6 µg/litre) and ND to 0.56 µg/litre in 5 domestic effluents.
It was concluded by the authors that the water pollution in the area
was due to a combination of pollution sources of low concentrations
(Ishikawa et al., 1985b). TCPP was detected at 0.06 µg/litre only in

one of the "other industrial sites" and was not detected in other
industrial effluents. TCPP was found at only one of the sewage
treatment plants (at 0.98 µg/litre in the influent and 0.32 µg/litre
in the effluent).

TDCPP was detected at concentrations ranging from trace to 0.22
µg/litre in water from water treatment plants in Japan (Takahashi &
Morita, 1988).

In 1979 a survey of drinking-water from treatment plants
throughout Canada was carried out. Samples were taken approximately 3
months apart in August/September and again in November/ December.
TDCPP was found at levels ranging from 0.0003 to 0.023 µg/litre in the
drinking-water supply of 15 Canadian cities. It was not detected in
drinking-water from 14 other cities (Williams & LeBel, 1981).

The concentration of TDCPP in drinking-water samples (one sample
at each station) collected in 1980 from 12 Canadian Great Lakes
municipalities ranged up to 0.0157 µg/litre during January and from
0.0001 to 0.0046 µg/litre during August (Williams et al., 1982).
Drinking-water samples (two samples of each station) collected from
six Eastern Ontario water treatment plants, in the period June-October
1978, contained 0.0002 to 0.0018 µg/litre (LeBel et al., 1981).

In a survey of organic effluent pollutants from three Swedish
waste water treatment plants, Paxéus (1996) found TDCPP at
concentrations of < 0.5 to 3 µg/litre.

5.1.3 Sediment

In 1975, 100 samples and, in 1978, 114 samples of sediment were
analysed for the presence of TDCPP in Japan. No TDCPP was found (limit
of determination in 1975 was 0.002-0.05 and, in 1978, 0.0001-0.06
mg/kg) (Environmental Agency Japan, 1983, 1987).

In a survey in 1980, four out of six samples of sediment
collected from a river and the sea near Kitakyushu City, Japan,
contained TDCPP at concentrations of 9-17 µg/kg (limit of
determination, 5 µg/kg) (Ishikawa et al., 1985a).

Twenty-four samples of sediment were collected and analysed for
the presence of TDCPP and TCPP in Japan in 1984. None of the samples
contained TDCPP (limit of determination, 0.03-0.06 mg/kg) or TCPP
(limit of determination, 0.011-0.05 mg/kg) (Environmental Agency
Japan, 1987; personal communication from the Japanese Ministry of
Health and Welfare to the IPCS, July 1993).

5.1.4 Biota

In 1975 and in 1978 samples of Japanese fish were analysed for
the presence of TDCPP. In 1975, 7/94 samples contained TDCPP at
concentrations of 0.015-0.025 mg/kg and in 1978 0/93 samples contained

TDCPP (limit of determination, 0.001-0.03 mg/kg) (Environmental Agency
Japan, 1983, 1987).

5.1.5 Food

In a market-basket survey of 234 food items conducted over a
10-year period between 1982 and 1991, TCPP was found 3 times. Residues
found in raw peach and raw pear were 0.009 mg/kg (limits of detection
unspecified) (Kan-Do Office and Pesticides Team, 1995).

5.2 General population exposure

5.2.1 Adipose tissue

In a series of studies (LeBel & Williams, 1983, 1986; LeBel et
al., 1989), TDCPP was detected in human adipose tissue. In initial
studies, concentrations ranged from not detectable (< 0.001 µg/kg) to
257 µg/kg. In later studies, samples from 4 out of 6 cities showed no
detectable TDCPP, whilst in the other two concentrations ranged up to
32 µg/kg.

5.2.2 Biological fluids

Using NCI mass spectrometry with a limit of detection of 0.01 µg,
Hudec et al. (1981) found TDCPP in the seminal fluid of 34 out of 123
student donors. The TDCPP concentrations ranged from 5 to 50 µg/litre.

6. KINETICS AND METABOLISM IN LABORATORY ANIMALS

6.1 TCPP

No data are available on the kinetics or metabolism of TCPP.

6.2 TDCPP

The only data available derive from studies in rats.

Groups of 2-8 male Sprague-Dawley rats received an unstated
amount of ¹⁴C-TDCPP by intravenous injection (Lynn et al., 1981). The
position of the radiolabel was not specified. Urine, faeces and
expired air were collected for 24-h periods over 5 days; bile and
plasma samples were collected over 24 h only. Total radiolabel and
tissue concentrations of TDCPP were assessed in most major organs at 5
min, 30 min, 8 h, 24 h and 5 days after injection. The major
metabolite isolated from urine, faeces and bile was
1,3-dichloro-2-propyl phosphate (BDCP); in addition
1,3-dichloro-2-propanol and a dimethyl derivative of BDCP were
identified in urine. There was also substantial elimination of ¹⁴CO₂
via exhaled air. The tissue distribution studies indicated
distribution of the parent compound and the major metabolite
(1,3-dichloro-2-propyl phosphate) throughout the body. On completion
of 5 days collection, approximately 96% of the administered
radiolabelled material had been recovered in the urine, faeces or
exhaled air.

Similar results were reported following dermal application of 0.9
mg/kg and oral administrations of up to 22 mg/kg (Nomeir et al., 1981;
Minegishi et al., 1988).

Following the intraperitoneal administration of ¹⁴C-TDCPP to
male Sprague-Dawley rats, urine collected over 24 h contained a major
metabolite, bis(1,3-dichloro-2-propyl) phosphate (BDCPP) (Lynn et al.
1981). In rats receiving intravenous injection, 54% of the radiolabel
was excreted in the urine after 5 days; 62% of the urinary label was
BDCPP (Lynn et al., 1980,1981).

Nomeir et al. (1981) studied the metabolism of ¹⁴C-TDCPP in
rats. Labelled TDCPP was distributed rapidly throughout the body
following either oral or dermal administration or intravenous
injection. Elimination of TDCPP was primarily in the bile, faeces and
urine, but some was expired as C0₂. About 80% of the dose was
eliminated within 24 h, but traces of radioactivity were found in most
tissues 10 days following exposure.

In a similar study, Minegishi et al. (1988), using male Wistar
rats, showed, after 168 h of an oral administration of 21.5 mg/kg in
olive oil, a recovery of 43.2% in the urine, 39.2% in the faeces and
16.2% in the expired air.

Six hours after intravenous administration of ¹⁴C-TDCPP (40.7
mg/kg) to CD-1 mice, binding of TDCPP-derived radioactivity was
detected in isolated RNA, DNA and protein from liver, kidney and
muscle. The maximum levels in RNA, DNA and protein were 28, 8.3 and 57
nmoles/kg, respectively (Morales & Matthews, 1980).

TDCPP was rapidly metabolized in vitro by an NADPH- dependent
microsomal mixed-function oxidase system and glutathione
S-transferases from rat liver to BDCPP, 1,3-dichloro-2-propanol,
3-chloro-1,2-propanediol, and one metabolite which was probably a
glutathione conjugate (Nomeir et al., 1981; Sasaki et al., 1984).

7. EFFECTS ON LABORATORY MAMMALS AND IN VITRO TEST SYSTEMS

7.1 Single exposure

7.1.1 TCPP

Acute oral LD₅₀ values for TCPP in rat have been reported in a
series of studies, as presented in Table 1, and range between 931 and
4200 mg/kg body weight for males and 707 and 2500 mg/kg body weight
for females.

LC₅₀ values for inhalation exposure to TCPP administered as an
aerosol to rats are given in Table 2.

Dermal LD₅₀ values for the rat and for the rabbit are above 2000
mg/kg body weight (Gordon, 1980; Smithey, 1981c; Cuthbert, 1989f).

7.1.2 TDCPP

Slc/ddY mice (10 male, 10 female per group) were given a single
oral intubation of TDCPP in olive oil and were observed for 14 days.
There were 7 dose groups and a control group for males and 6 dose
groups and a control group for females. The dose range was 2210-3500
mg/kg for males and 1890-2780 mg/kg for females. Clinical signs
included ataxia, hyperactivity and convulsion (incidence not
reported). LD₅₀ values for male and female mice were 2670 mg/kg
(range 2520-2830) and 2250 mg/kg (range 2120-2390 mg/kg), respectively
(Kamata et al., 1989).

In two different studies using male and female Sprague-Dawley
rats, Cuthbert (1989a,b) investigated the oral and dermal LD₅₀ of
TDCPP. In the oral study, clinical signs noted 1-5 days after dosing
included hypokinesia, piloerection, soiled coats, ataxia,
chromodacryorrhoea, rhinorrhoea and salivation. In the dermal study,
no death occurred and no clinical signs were noted 24 h after
administration. In both cases the LD₅₀ was evaluated as greater than
2000 mg/kg.

When Anderson (1990b) administered a TDCPP-containing aerosol to
groups of 5 male and female Sprague-Dawley rats, the LC₅₀ was greater
than 5220 mg/m³.

7.2 Short-term exposure

7.2.1 TCPP

Groups of rats fed ad libitum for 14 days at levels of 4200,
6600, 10 600 and 16 600 mg/kg diet presented minimal evidence of
toxicity. No treatment-related changes were seen in haematology,
clinical chemistry or cholinesterases activity. Increased relative and
absolute liver weights were reported without concomitant
histopathological change (Stauffer, 1980).

7.2.2 TDCPP

No histological effects were observed in the liver, kidneys or
gonads of rats given daily doses of 250 mg/kg per day for 10 days
(Ulsamer et al., 1980).

7.3 Long-term exposure

7.3.1 TCPP

No data on TCPP are available.

Table 1. Oral LD₅₀ values for TCPP in rats

Strain^a LD₅₀ (mg/kg body weight) Clinical signs Reference
Male Female

Sprague-Dawley 4200 2800 "depression", tremors, lacrimation, Stauffer, 1979
salivation, convulsion

Sprague-Dawley 2710 - "depression" and tremors at Stauffer, 1972
dosage > 1000 mg/kg

Sprague-Dawley 2000 1260 "depression" and intermittent muscle Stauffer, 1970
spasm at 464 mg/kg; salivation ataxia
and spasmodic jumping at high dose

Sprague-Dawley 931 - "depression" hunched posture, decreased Safepharm (undated/a)
respiratory rate, increased salivation,
laboured respiration

Sprague-Dawley 1310 - hunched posture, decreased respiratory Safepharm (undated/c)
rate, signs of lethargy, ataxia, laboured
respiration

Sprague-Dawley - 980 ataxia, hunched posture, decreased Safepharm (undated/d)
respiratory rate, lethargy, laboured
respiration

Sprague-Dawley - 1548 ataxia, hunched posture, lethargy, Safepharm (undated/e)
piloerection, decreased respiratory rate,
laboured respiration

NS - 1011 piloerection, hunched posture, waddling Huntingdon Life
gait, lethargy, respiratory distress, Sciences, 1997b
increased salivation, clonic convulsions

NS - 707 hunched posture, waddling gait, lethargy, Huntingdon Life
respiratory distress, increased salivation Sciences, 1997a

Table 1. (Continued)

Strain^a LD₅₀ (mg/kg body weight) Clinical signs Reference
Male Female

NS 1546 1017 increased or reduced activity; oral, nasal, Mehsl, 1980
perional and ocular discharge, hunching,
rough coat, aggression, diarrhoea, anorexia
and sporadic twisting

NS 1824 1101 reduced activity, oral/nasal discharge, Anon, 1981a
convulsion, emaciation, prostration

NS 1750 1150 - Bayer AG, 1990
(unpublished data)

NS 1419^b Stauffer, 1978
(Report No. T6539)

NS >2000^b,c After 1-3 days, reduced activity, Cuthbert, 1989d
piloerection and ataxia

^a NS = not specified
^b Separate values for males and females not given
^c 10 animals (5 of each sex)

Table 2. LC₅₀ values for TCPP administered as aerosol to rats

Duration LC₅₀ (mg/litre) Remarks^a Reference
(h)

1 > 17.8 10 animals (5 of each sex), whole Mehlman & Smart, 1981
body exposure; clinical signs:
decreased activity, partially closed
eyes, swollen eye lids, lacrimation

4 > 4.6 clinical signs: mild lethargy and matted fur Stauffer, 1979

4 > 7.9 10 animals (5 of each sex) Anderson, 1990a

4 approximately 5 (female) whole body exposure (one exposure Mehlman & Singer, 1981
> 5 (male) level only; 0/5 male; 3/5 female);
clinical signs: decreased activity, increased
salivation

^a There were no deaths in the first three studies but three females out of five died in the study of
Mehlman & Singer (1981)

7.3.2 TDCPP

Slc/ddY mice (12 male, 12 female per group) were administered
diets containing 0, 100, 400, 1300, 4200 or 13 300 mg/kg diet for 3
months. The daily intake of TDCPP reported by the authors was 0, 13,
47, 171, 576 or 1792 mg/kg body weight per day for males and 0, 15,
62, 214, 598 or 1973 mg/kg body weight per day for females. The
animals in the highest exposure groups showed emaciation, rough hair
and tremor (incidence not reported) and all animals died within one
month. Haemoglobin concentration was decreased in males and females by
13% and 11%, respectively, in the group treated with 4200 mg/kg diet.

There was a progressive increase in serum alkaline phosphatase
and serum alanine aminotransferase activities with increasing
exposure, but the change was not statistically significant after 3
months. There was also an increase in relative liver weight in males
(statistically significant in the 1300 and 4200 mg/kg groups where the
increases were 32% and 51%, respectively) and females (statistically
significant in the 400, 1300 and 4200 mg/kg groups, where the
increases were 16%, 29% and 51%, respectively). There was also an
increase in relative kidney weight in males (statistically significant
in the 4200 mg/kg group where the increase was 39%) and females
(statistically significant in the 1300 and 4200 mg/kg groups where the
increases were 34% and 40%, respectively). A slight necrosis was
reported in the liver of two females of the 4200 mg/kg group. In this
study the NOEL for the increase in relative liver weight in males was
47 mg/kg body weight per day and in females 15 mg/kg body weight per
day; the LOEL in males was 171 mg/kg body weight per day and in
females 62 mg/kg body weight per day (Kamata et al., 1989).

7.4 Skin and eye irritation or sensitization

7.4.1 TCPP

7.4.1.1 Skin irritation

TCPP was investigated in New Zealand white rabbits for dermal
irritation. Two reports classified TCPP as mild or slightly irritant
to rabbit skin (Cuthbert, 1989e; Safepharm, 1979c).

In a study conducted under OECD Test Guideline 404, 0.5 ml TCPP
was applied to the skin of three New Zealand white rabbits under a
semi-occlusive dressing for 4 h (Liggett & McRae, 1991a). Slight
erythema (grade 1) was noted in one animal on day 1 only. Thereafter,
there were no signs of skin irritation.

In two different studies, 0.5 ml of TCPP was applied to two test
sites, one abraded and one intact skin of the back of six New Zealand
white rabbits under an occlusive binder for 24 h. Using the technique
of Draize test, sites were scored for irritancy at 24 and 72 h after
application. In both case the test material was classified as not
irritant (Smithey, 1980b, 1981b).

7.4.1.2 Eye irritation

In a study conducted under OECD Test Guideline 405, 0.1 ml TCPP
was instilled into one eye of each of three New Zealand white rabbits
(Liggett & McRae, 1991b). Slight conjunctival redness (grade 1) was
seen in each animal on day 1 only. Thereafter, there were no signs of
eye irritation.

Three older studies conducted under different guidelines using
albinos or New Zealand white rabbits reported no signs of eye
irritation (Safepharm, 1979b; Smithey, 1980a, 1981a). In a limited
study, Cuthbert & Jackson (1990b) reported that TCPP was slightly
irritant, but the effect was quickly reversible in New Zealand white
rabbits.

7.4.1.3 Sensitization

TCPP was examined using the Magnuson and Kligman method for
possible contact sensitization potential in guinea-pigs. TCPP produced
no skin sensitization(Safepharm, 1979a).

7.4.2 TDCPP

7.4.2.1 Skin irritation

The acute dermal irritation potential of TDCPP was investigated
in three New Zealand white rabbits. Well defined (score 2) erythema
was recorded in 2 animals 1 h after patch removal. The third animal
showed very slight erythema at 1 h. By 48 h all treated sites were
normal. TDCPP was classified as irritant to rabbit skin (Cuthbert,
1989c).

7.4.2.2 Eye irritation

New Zealand white rabbits were used to evaluate the eye
irritation potential of TDCPP. Slight conjunctival redness and slight
discharge were noted 1 h after instillation. By 24 h after
instillation, all treated eyes were normal. It was concluded that
TDCPP was slightly irritant to the rabbit eye (Cuthbert & Jackson,
1990a).

7.4.2.3 Sensitization

No data on the skin sensitization potential of TCPP are
available.

7.5 Reproductive toxicity, embryotoxicity and teratogenicity

7.5.1 TCPP

No studies concerning the possible reproductive toxicity,
embryotoxicity or teratogenicity of TCPP have been reported.

7.5.2 TDCPP

Female Wistar rats (15-24 per group) were given 25, 50, 100, 200
or 400 mg/kg body weight by oral intubation on days 7 to 15 of
gestation. In the 400 mg/kg group, there was severe maternal toxicity;
maternal body weight gain and food consumption were markedly
suppressed and 11 out of 15 dams died. Clinical signs in dams at 400
mg/kg included piloerection, salivation and haematuria. Fetal death
was markedly increased at 400 mg/kg. In the 200 mg/kg group there was
a statistically significant increase in relative kidney weight (15%
increase) in dams. No effects on dams were seen at lower exposures.
There was no evidence of an increased number of fetal deaths, of
abnormal fetal development, or of malformation at an exposure of 200
mg/kg or less. In this study the NOEL and LOEL for maternal toxicity
were 100 mg/kg and 200 mg/kg body weight per day, respectively, and
the NOEL and LOEL for fetotoxicity were 200 mg/kg and 400 mg/kg body
weight per day, respectively (Tanaka et al., 1981).

In a fertility study, male rabbits were given oral gavage TDCPP
doses of 2, 20 or 200 mg/kg body weight per day for 12 weeks. The
treatment did not affect mating behaviour, fertility, sperm quality or
sperm quantity. Kidney and liver weight were increased at 200 mg/kg
body weight per day, but it was reported that no histopathological
lesions were seen in kidneys, liver, pituitaries, testes or epididymes
(Wilczynski et al., 1983).

7.6 Mutagenicity and related end-points

7.6.1 TCPP

There was no clear evidence from a battery of assays for
mutagenicity and related effects to suggest that TCPP was genotoxic
(Tables 3 and 4).

TCPP produced no gene mutations in strains TA1535, TA1537,
TA1538, TA97, TA98 and TA100 in any of six Salmonella/microsome plate
assays and one Escherichia coli (Stauffer, 1978c; Nakamura et al.,
1979; Anon, 1980; Zeiger et al., 1992; Mehlman et al., 1980; Parmar,
1977; Kouri & Parmar, 1977) nor in a yeast gene mutation assay
(Stauffer, 1978c) in either the presence or absence of metabolic
activation. One mouse lymphoma assay gave equivocal results (Anon,
1981b), but a second mouse lymphoma assay was negative in the presence
and absence of metabolic activation (Stauffer, 1978a). An in vitro
assay for unscheduled DNA synthesis (UDS) in a primary culture of rat
hepatocytes gave a negative result (Bayer, 1991, Report No. 20393),
whereas the results of in vitro UDS assays in WI-38 cells (Stauffer,
1978b) were equivocal in the presence and absence of metabolic
activation. Two out of three cell transformation assays in BALB/3T3
cells gave negative results in the absence of metabolic activation
(Stauffer, 1978b, 1980, Report No. T10182), whereas the third was
equivocal (Stauffer, 1978, Report No. T6357).

TCPP caused no chromosomal damage in bone marrow in three in
vivo cytogenetic assays using oral or subcutaneous administration to
rats (Stauffer, 1978, Report No. T6539) and intraperitoneal
administration to mice (Bayer, 1991, Report No. 20029).

7.6.2 TDCPP

TDCPP has been tested for mutagenic effects in vitro and in
vivo (Tables 5 and 6).

TDCPP has been investigated several times in bacterial gene
mutation studies using the Salmonella/microsome mutation test.
Mortelmans et al. (1986) reported the findings of four tests performed
in three different laboratories which tested TDCPP using strains
TA100, TA1535, TA98, TA97 (2 labs) and TA1537 (2 labs) in the presence
and absence of metabolic activation by S9 from Aroclor 1254 activated
livers of rats and hamsters. There was no evidence of mutagenicity in
the absence of S9, but all three laboratories obtained some positive
results in the presence of S9. Positives were reported in at least
some of the laboratories for strains TA97, TA100 and TA1535 with both
hamster and rat S9. All three laboratories reported positive findings
in TA100. Two other studies (Gold et al., 1978; Sœderlund et al.,
1985) also found a mutagenic response in TA100 in the presence of
metabolic activation. Brusick et al. (1980) found no mutagenicity in
strains TA1535 or G46 in the presence or absence of S9, but obtained
different results in TA100 depending upon the source of the S9 used in
the assay: mutagenic activity was seen when they used S9 from rat
liver activated with Aroclor 1254 or phenobarbital but not with S9
from human liver or from mouse liver activated with Aroclor 1254 or
phenobarbital. Taken as a whole, the results of bacterial tests show
TDCPP to have mutagenic potential.

No mutagenic activity was noted in strains TA98, TA100, TA1535 or
TA1537 when they were incubated with untreated or
beta-glucuronidase-treated urine from TDCPP-treated mice (Brusick et
al., 1980). The CD1 mice had been given oral doses of 0.05, 0.17 or
0.5 ml/kg body weight per day, and urine was collected on the fourth
day of treatment. It was unclear from the report of the study whether
or not the urine samples had been tested for mutagenicity in the
presence of any metabolizing system.

TDCPP did not induce gene mutations in the mouse lymphoma assay
either in the absence or presence of various exogenous metabolic
systems (S9 from rat or mouse liver induced with either Aroclor 1254
or phenobarbital) when tested up to a concentration causing a 50%
reduction in cell growth (Brusick et al., 1980).

Table 3. Mutagenicity and related end-points for TCPP in vitro

Test system Concentration Activation Result^a Reference
+S9 -S9

Bacterial gene mutation assays

Salmonella typhimurium
TA100, TA1535 0.3-10 µmol/plate + + - Nakamura et al., 1979

Salmonella typhimurium
TA97, TA98, TA100, TA1535, TA1537 3.3-1000 µg/plate + + - Zeiger et al., 1992

Salmonella typhimurium
TA98, TA100, TA1535, TA1537, TA1538 0.001-5 µl/plate + + - Stauffer, 1978c

Salmonella typhimurium
TA98, TA100, TA1535, TA1537, TA1538 0.03-1 µl/plate + + - Anon, 1980

Salmonella typhimurium
TA98, TA100, TA1535, TA1537, TA1538 0.03-0.33 µl/plate + + - Mehlman et al., 1980

Salmonella typhimurium
TA98, TA100, TA1535, TA1537, TA1538 1-50 µl/plate + + - Parmar, 1977

Escherichia coli
Pol A+, Pol A- 2-20 µl/plate + + - Kouri & Parmar, 1977

Yeast gene mutation assay

Saccharomyces cerevisiae 0.001-5 µl/plate + + - Stauffer, 1978c
L5178Y TK+/- 0.08-0.48 µl/ml + + - Stauffer, 1978c
L5178Y TK+/- 0.006-0.028 µl/ml + + ± Anon, 1981b

Unscheduled DNA synthesis
Human diploid WI-38 cells 0.1-5 µl/ml + + ± Stauffer, 1978b

Table 3. (Continued)

Test system Concentration Activation Result^a Reference
+S9 -S9

Human diploid WI-38 cells 0.1-100 µl/ml + - ± Stauffer, 1978b
Rat liver primary cells 12.5-200 µg/ml + - - Bayer, 1991
(Report No. 20393)
Cell transformation assays
BALB/3T3 cells 0.00125-0.02 µl/ml - + ± Stauffer, 1978
(Report No. T6357)
BALB/3T3 cells 0.00125-0.02 µl/ml - + - Stauffer, 1978b
BALB/3T3 cells 0.00015-3 µl/ml - + - Stauffer, 1980
(Report No. T10182)

^a ± = equivocal result

Table 4. In vivo mutagenicity assays for TCPP

Species Route of administration Dose Result Reference

Cytogenetic assays

Rat oral 0.011, 0.04 and no chromosomal Stauffer, 1978
0.11 ml/kg body weight aberrations (Report No. T6539)

Rat subcutaneous 0.011, 0.04 and no chromosomal Stauffer, 1978
0.11 ml/kg body weight aberrations (Report No. T6539)
on 5 consecutive days

Mouse intraperitoneal 350 mg/kg body weight "no clastogenic effects" Bayer, 1991
(Report No. 20029)

Table 5. Mutagenicity and related end-points for TDCPP in vitro

Test system Concentration Result Reference

Bacterial tests

S. typhimurium
TA100, TA1535, G46 10200 µg/plate + Brusick et al., 1980

S. typhimurium
TA97, TA98, TA100, TA1535, TA1537 10 to 10 000 µg/plate + Mortelmans et al., 1986

S. typhimurium
TA100 50-1000 µg/plate + Soderlund et al., 1985

S. typhimurium
TA100 50-250 µg/plate + Gold et al., 1978

Mouse lymphoma assay
L5178Y cells up to 0.07 µl/ml - Brusick et al., 1980

SCE assay
L5178Y cells 0.005-0.07 µl/ml ? Brusick et al., 1980

Chromosomal aberration assays
L5178Y cells 0.01-0.1 µl/ml + Brusick et al., 1980
CHL cells ? + Kawachi et al., 1980;
Ishidate et al., 1981
Human fibroblasts ? - Kawachi et al., 1980;
Ishidate et al., 1981

Cell transformation
BALB/3T3 cells up to 0.312 µl/ml - Brusick et al., 1980

Table 6. In vivo mutagenicity of TDCPP

Test system^a Dose Result Reference

Insect assay
SLRL mutations in Drosophila 2.5 and 25% in feed - Brusick & Jagannath, 1977;
Brusick et al., 1980
Mammalian bone marrow assays
SCE & CA in CD1 mice 0.05-0.5 ml/kg - Brusick et al., 1980
body weight
Micronuclei in mice 2000 mg/kg body weight - Thomas & Collier, 1985

^a SLRL = sex-linked recessive lethal
SCE = sister-chromatid exchange
CA = chromosome aberration

TDCPP was also tested for in vitro chromosome effects, i.e.
chromosomal aberrations (CA) and sister chromatid exchanges (SCE),
using mouse lymphoma (L5178Y) cells at concentrations up to those
causing a 50% reduction in growth rate (Brusick et al., 1980). Tests
were performed in the absence and presence of various exogenous
metabolic systems (S9 from mouse liver induced with either Aroclor
1254 or phenobarbital). The results for SCEs were equivocal, whereas
those for CAs showed increased numbers of chromosomal aberrations
(excluding gaps) with both metabolic activation systems. Induction of
SCEs was reported in a separate study by Gold et al., 1978. Incomplete
reports of in vitro cytogenetic studies claimed that TDCPP caused
chromosomal aberrations in CHL cells but not in human fibroblasts
(Kawachi et al., 1980; Ishidate et al., 1981).

TDCPP did not induce primary DNA damage as measured indirectly as
unscheduled DNA synthesis in a primary culture of rat hepatocytes
(Williams et al., 1989). In vivo covalent binding studies in CD1
mice have revealed that TDCPP and/or its metabolites can bind to
cellular DNA from the liver and kidney (Morales & Matthews, 1980).
Section 6.2 includes other details of this study.

TDCPP did not induce sex-linked recessive lethal mutations in
Drosophila melanogaster (Brusick et al., 1980).

TDCPP did not induce SCEs or CAs in bone marrow cells of CD1 mice
(sex not reported) following either a single oral gavage dose of 0.05,
0.17 or 0.5 ml TDCPP/kg body weight (using bone marrow harvest times
of 6, 24 and 48 h post-dosing) or 5 consecutive daily oral exposures
at the same dose levels with a harvest time of 6 h after the last dose
(Brusick et al., 1980).

TDCPP did not induce micronuclei in polychromatic erythrocytes in
the bone marrow of either sex of mice (strain not reported) that had
been given a single dose of 2000 mg TDCPP/kg body weight by an
unspecified route of administration (Thomas & Collier, 1985). The
ratio of normochromatic erythrocytes to polychromatic erythrocytes was
not elevated at any of the sampling times (24, 48 and 72 h
post-dosing), but, as there was systemic toxicity seen in the treated
mice, the TDCPP must have entered the blood circulation and thus the
bone marrow cells must have been exposed to TDCPP and/or its
metabolites.

TDCPP did not induce morphological cell transformations in
BALB/3T3 cells in two independent tests in the absence of any
metabolic activation (Brusick et al., 1980).

7.7 Carcinogenicity

7.7.1 TCPP

No data on the carcinogenic potential of TCPP are available.

7.7.2 TDCPP

Groups of 50 male and 50 female Sprague-Dawley rats received
approximately 0, 5, 20 and 80 mg TDCPP/kg per day by dietary
administration for 2 years (Aulette & Hogan, 1981). An additional 10
animals per group were killed after 1 year for interim investigations.
Examinations included body weight gain and food consumption,
haematology, clinical chemistry, urinalysis, ophthalmoscopy, organ
weights and extensive macroscopic and microscopic investigations.

Increased mortality was reported in males at 80 mg/kg per day.
Reduced body weight gain was noted in males and females at 80 mg/kg
per day (approximately 20% lower than control), although food
consumption was unaffected. Ophthalmoscopy revealed sacculations on
the retinal arterioles in one male at 20 mg/kg per day and four males
and four females at 80 mg/kg per day at 80 or 104 weeks. Red blood
cell values were reduced amongst males and females at 80 mg/kg per
day. In addition, there was a slight decrease in plasma cholinesterase
activity in females at 80 mg/kg per day, although erythrocyte
cholinesterase was unaffected.

Increased liver, kidney and thyroid weights were reported at 12
and 24 months at the highest dose in both males and females.
Microscopic pathology changes were observed in liver, kidneys, testes
(and associated tissues), bone marrow, spleen and parathyroids. In the
liver, a slight increase in the occurrence of local hepatocellular
alterations was noted in males and females at 80 mg/kg per day (males,
29/46 compared to 20/45 in controls; females, 35/50 compared to 15/49
in controls). In addition, there was a slight increase in the
incidence of dilated sinusoids in the liver at this exposure level
(males, 12/46 compared to 4/55; females, 18/50 compared to 7/49). In
the kidneys, an increased occurrence of hyperplasia in the convoluted
tubules was observed in all groups of treated males and females
(males, 2/45, 10/49, 28/48, 24/46; females 0/49, 1/48, 3/48, 22/50).
In addition, there was an increase in the occurrence of chronic
nephropathy in males and females at 80 mg/kg per day (males, 39/46
compared to 25/45; females, 25/50 compared to 7/49). In the
seminiferous tubules there was a slight increase in the occurrence of
germinal epithelial atrophy and oligospermia (30/43, 29/48, 42/47,
44/45); eosinophilic material in the tubular lumen (2/43, 4/48, 12/47,
11/45); sperm stasis (5/43, 5/45, 11/47, 14/45); periarteritis nodosa
(5/43, 10/48, 19/47, 14/45). Seminal vesicle atrophy and decreased
secretory products were reported in all treated groups. In the
epididymides males given 80 mg/kg per day had an increased incidence
of oligospermia and degenerated seminal products.

An increased incidence of bone marrow erythroid/myeloid
hyperplasia was recorded in males and females at 80 mg/kg (males,
21/42 compared to 12/40 in controls; females, 18/44 compared to
13/41). However, no samples were taken from other treated groups.

An increased incidence of spleen erythroid/myeloid metaplasia was
seen in males and females at 80 mg/kg per day (males, 10/45 compared
to 12/45 in controls; females, 33/50 compared to 30/49). Again there
were insufficient tissue samples taken from other treatment groups to
draw firm conclusions about the dose-response relationship. Similarly,
there was an increased occurrence of parathyroid hyperplasia in males
and females at 80 mg/kg per day (males, 12/31 compared to 1/21;
females, 9/25 compared to 6/26). Insufficient samples were taken from
other treated groups to determine the dose-response relationship.

Neoplastic changes were observed in the liver, kidneys, testes,
brain, thyroid and adrenals. In liver, the occurrence of benign
neoplastic nodules was 2/45, 7/48, 1/48, 13/46 in males and 1/49,
1/47, 4/46, 8/50 in females; the incidence of carcinoma was 1/45,
2/48, 3/48, 7/46 in males and 0/49, 2/47, 2/46, 4/50 in females. In
the kidneys the incidence of renal cortical tumours (benign and/or
malignant) was 1/45, 3/49, 9/48, 32/46 in males and 0/49, 1/48, 8/48,
49/50 in females. The incidence of benign testicular interstitial
tumours was 7/43, 8/48, 23/47 and 36/45. A slight increase in the
incidence of brain astrocytomas was observed in males receiving 80
mg/kg per day (4/46 compared to 0/44 in controls) and a single
oligodendroglioma was observed amongst males and females given 80
mg/kg per day.

The occurrence of thyroid adenomas was increased amongst females
at 80 mg/kg per day (5/49 compared to 1/42 in controls). In addition,
a slight increase in the occurrence of parafollicular cell adenomas
was noted in males and females at 80 mg/kg per day (males, 3/41
compared to 0/40; females, 4/49 compared to 2/42). The occurrence of
adrenal cortical adenomas was increased only in females at 80 mg/kg
per day (19/49 compared to 8/48 in controls).

It was concluded that TDCPP is carcinogenic at all exposure
levels that were tested in both sexes of rats based on the increased
occurrence of liver carcinomas. Kidney, testicular and brain tumours
were also found. In addition, there were non-neoplastic adverse
effects in bone marrow, spleen, testis, liver and kidney. Effects in
the kidney and testis occurred at all exposure levels. Only the
animals in the highest dose and control groups were evaluated for
effects in the bone marrow and spleen. It was impossible, therefore,
to determine the dose-response relationship for these effects.

7.8 Other studies

7.8.1 Immunotoxicity

7.8.1.1 TCPP

No data on the immunotoxic potential of TCPP are available.

7.8.1.2 TDCPP

The effects of TDCPP on immunological functions and host
susceptibility to infectious agents were examined following exposure
in adult mice. Groups of 7-10 B6C3F₁ mice received 0, 0.25, 2.5 or 25
mg/kg per day by subcutaneous injection for 4 days. Immunological
tests included bone marrow cellularity and colony formation,
lymphoproliferative responses to mitogens, delayed hypersensitivity
and serum IgG, IgM, and IgA concentrations. Other end-points examined
included clinical signs of toxicity, haematology, clinical chemistry,
body weight, and the weight of thymus, spleen and liver. There were no
clinical signs of toxicity, no significant effects on body weight,
organ weight, and no abnormal histopathology.

TDCPP treatment induced minimal changes in immune functions and
host susceptibility only at the highest dose tested. This was
indicated by decreased (P < 0.05) lymphoproliferative responses to
mitogens and increased tumour takes following tumour cell challenge,
where there was an increase (P < 0.05) in the number of animals with
tumours (8/10 versus 5/10 in control) but no change in the latency
period (Luster et al., 1981).

7.8.2 Neurotoxicity

7.8.2.1 TCPP

The neurotoxic potential of TCPP in adult white Leghorn hens was
evaluated by Sprague et al. (1981). A group of 18 hens received an
initial oral dose of 13.23 g TCPP/kg body weight followed by the same
treatment 3 weeks later. The animals were sacrificed 3 weeks after the
second dose. Loss of body weight, transient reduction in food
consumption and one death were reported for the treated animals. Egg
production ceased shortly after the first dose and there was severe
loss of feathers. No behavioural or histological evidence for delayed
neurotoxicity was seen.

7.8.2.2 TDCPP

Chickens exposed orally to TDCPP at doses of 0.6, 1.2, 2.4 or 4.8
g/kg body weight per day for 5 days exhibited leg and wing weakness at
doses of 1.2 g/kg or more and 100% mortality at 4.8 g/kg body weight,
while lower dose levels caused leg and wing weakness (Ulsamer et al.,
1980).

White Leghorn hens, 12 months old, were orally exposed to 420 mg
TDCPP/kg body weight per day for five consecutive days as specified in
the procedure outlined in Navy MIL-H-19457B (SHIPS) protocol. After 21
days of observation there were no signs of neurotoxicity, whereas
TOCP, used as positive control, induced inability to walk,
hypertension, ataxia and prostration (Bullock & Kamienski, 1972).

8. EFFECTS ON HUMANS

8.1 TCPP

No data concerning the effects of TCPP on humans are available.

8.2 TDCPP

A retrospective cohort study examined mortality in 289 workers
employed in the manufacture of TDCPP. The cohort included all male
workers employed for 3 months or more in a manufacturing plant in the
USA during 1956-1977. The subjects were followed up until 1980.
Overall mortality in the subjects was 75% of the normal expected for
the male population in the USA. Three cases of cancer of the lung were
identified (0.8 cases expected), but all three decedents were moderate
to heavy smokers. Air samples were not taken at the time of exposure
but breathing zone samples were taken from other area/job
classifications in 1981 and all contained less than 0.4 µg/m³ (7 ppb)
of TDCPP. The slight increase in the number of people with lung cancer
was not statistically significant and its association with TDCPP
exposure remains unclear due to the small size of this study, the
absence of evidence of exposure to TDCPP, the effect of possible mixed
exposure to other chemicals and other confounding factors including
smoking history (Stauffer, 1983b).

During 1981 workers at a TDCPP manufacturing plant in the USA had
their health assessed in physical examinations. The health reports of
93 potentially exposed workers from the factory were compared with the
health reports of 31 non-exposed workers who were matched for age,
alcohol consumption and smoking habits. The two groups of workers were
comparable with regard to chest X-ray results. Exposed workers had a
2-fold increase in the prevalence of "abnormal" electrocardiograms,
but fewer exposed workers had a history of heart disease. There were
no significant differences in any of the clinical chemistry parameters
investigated. The prevalence of minor respiratory disease was slightly
increased in exposed workers. The results of the study did not reveal
any significantly increased morbidity in workers exposed to TDCPP
(Stauffer, 1983a).

9. EFFECTS ON OTHER ORGANISMS IN THE LABORATORY AND FIELD

9.1 Microorganisms

The LC₅₀ for bacteria from sewage sludge was reported to be
> 10 000 mg/litre for TDCPP (Akzo, 1997b). No data were identified
for TCPP.

9.2 Aquatic organisms

9.2.1 Algae

The EC₅₀ for growth has been reported to be 47 mg TCPP/litre for
the green alga Selenastrum capricornutum (Akzo, 1997c). The
corresponding EC₅₀ in the same alga for TDCPP was 12 mg/litre (Akzo,
1997b). Exposure of the alga Scenedesmus subspicatus to TDCPP
(Amgard TDCP) at 10 mg/litre for 72 h had no effect on growth or
biomass (SafePharm, 1994).

9.2.2 Invertebrates

The 48-h LC₅₀ for Daphnia was reported to be 131 mg/litre
(measured concentration corresponding to 209 mg/litre nominal
concentration) for TCPP as Antiblaze 80 under static conditions
(Mobil, 1985a). A lower-observed-effect concentration (LOEC) (based on
nominal concentrations) of 33.5 mg/litre was determined on the basis
of behavioural observations.

A 21-day reproduction test using Daphnia magna showed a
no-observed-effect concentration (NOEC) of 32 mg/litre for TCPP based
on adult mortality. No reproductive effects were seen at lower
concentrations (SafePharm, undated/b).

A 48-h LC₅₀ of 4.6 mg/litre for Daphnia magna was reported
using TDCPP (Amgard TDCP), together with a NOEC of 1.8 mg/litre
(SafePharm, 1993a).

9.2.3 Fish

The 96-h LC₅₀ for the fathead minnow (Pimephales promelas) was
51 mg/litre (based on measured concentrations; equivalent to 98
mg/litre nominal concentration) under static conditions. The
corresponding LC₅₀ for bluegill sunfish (Lepomis macrochirus) was
180 mg/litre. The NOEC for both species was estimated to be 9.8
mg/litre for TCPP as Antiblaze 80 (Mobil 1985b,c).

The 96-h LC₅₀ for rainbow trout (Oncorhynchus mykiss) was 1.1
mg/litre for TDCPP (Amgard TDCP) and the NOEC 0.56 mg/litre
(SafePharm, 1993b). One out of 6 goldfish (Carassius auratus) died
after exposure to TDCPP at 1 mg/litre for 168 h and all fish died
after exposure to 5 mg/litre (Eldefrawi et al., 1977). The 96-h LC₅₀

values for killifish (Oryzias latipes) and goldfish
(Carassius auratus) were reported to be 3.6 and 5.1 mg/litre,
respectively, for a static exposure system. Killifish exposed to 3.5
mg/litre for 24 h showed spinal deformities (Sasaki et al., 1981).

9.3 Terrestrial organisms

An acute toxicity test in artificial soil on TDCPP (Amgard TDCP)
conducted according to OECD Guideline 207 on the earthworm
Eisenia foetida gave an LC₅₀ value after 14 h of 130 mg/kg soil and
a NOEC of 100 mg/kg soil (SafePharm, 1996c). The corresponding values

for TCPP (Amgard TMCP) were a 14-h LC₅₀ of 97 mg/kg and a NOEC of 32
mg/kg soil (SafePharm, 1996d).

10. EVALUATION

10.1 TCPP

Residues of TCPP are found infrequently and at low concentration
in food items. TCPP has not been found in drinking-water. The low
volatility of TCPP precludes significant exposure from air. Exposure
to TCPP from these sources will not present an acute hazard to the
general population. Although toxicological data from long-term studies
are limited, because of low exposure to TCPP the risk of adverse
health effects to the general population is negligible.

TCPP has been tested at three trophic levels for acute exposure
and two trophic levels for chronic exposure of organisms relevant to
the environment. The lowest reported chronic NOEC is more than 3
orders of magnitude higher than the highest reported concentration in
sewage effluent (Fig. 1). There will be no adverse effects on the
environment from the use of TCPP.

10.2 TDCPP

TDCPP has been tested at three trophic levels for acute exposure
and two trophic levels for chronic exposure of organisms relevant to
the environment. The lowest reported chronic NOEC is more than 3
orders of magnitude higher than the highest reported concentration in
sewage effluent and surface waters (Fig. 2). There will be no adverse
effects on the environment from the use of TDCPP.

Residues of TDCPP are found infrequently and at low concentration
in food items and drinking-water. The low volatility of TDCPP
precludes significant exposure from air. Exposure to TDCPP from these
sources will not present an acute hazard to the general population.
TDCPP was genotoxic in bacterial tests and in some in vitro
mammalian cell tests. However, it has not been sufficiently tested for
mutagenicity in vivo. TDCPP has been found to be carcinogenic in
rats. The mechanism of carcinogenicity has not be elucidated. The
exposure level leading to the residues found in humans is unknown.
Insufficient information, therefore, is available to estimate
accurately human risk. However, because of the low exposure, the risk
is expected to be low.

11. FURTHER RESEARCH

Further investigations of the tumorigenicity of TDCPP and the
mechanisms underlying it are needed.

TRIS(2-CHLOROETHYL) PHOSPHATE

A1. SUMMARY

Tris(2-chloroethyl) phosphate (TCEP) is a colourless to pale
yellow liquid, which is used as a flame retardant mainly in the
production of liquid unsaturated polyester resins. It is also used in
textile back-coating formulations, PVC compounds, cellulose ester
compounds and coatings. It is not volatile and its solubility in water
is 8 g/litre. It is soluble in most organic solvents. Its log
octanol/water partition coefficient is 1.7.

Analysis is by GC/MS. Concentration of TCEP from water prior to
analysis can be achieved using XAD resin or activated charcoal,
followed by extraction with various organic solvents.

TCEP is manufactured from phosphorus oxychloride and ethylene
oxide. Production and use of TCEP has been in decline since the 1980s.
Annual worldwide demand was less than 4000 tonnes in 1997.

TCEP is not readily biodegradable. Bioconcentration factors are
low and the half-life of elimination in fish is 0.7 h.

Traces of TCEP have been detected in river water, seawater,
drinking-water, sediment, biota (fish and shellfish) and in a few
samples of various foods.

In rats, oral doses of TCEP are absorbed and distributed around
the body to various organs, particularly the liver and kidney, but
also the brain. Metabolites in rats and mice include
bis(2-chloroethyl) carboxymethyl phosphate; bis(2-chloroethyl)
hydrogen phosphate; and bis(2-chloroethyl)-2-hydroxyethyl phosphate
glucuronide. Excretion is rapid, nearly complete and mainly via the
urine.

TCEP is of low to moderate acute oral toxicity (oral LD₅₀ in the
rat = 1150 mg/kg body weight).

In repeat dose studies, TCEP caused adverse effects on the brain
(hippocampal lesions in rats), liver and kidneys. The NOEL was 22
mg/kg body weight per day and the LOEL 44 mg/kg body weight per day
for increased weights of liver and kidneys in rats.

TCEP is non-irritant to skin and eyes, but has not been tested
for sensitization potential.

TCEP is not teratogenic. It adversely affects the fertility of
male rats and mice.

No conclusions can be drawn about the mutagenicity of TCEP as
in vitro test results were inconsistent and an in vivo bone
marrow micronucleus test gave equivocal results.

TCEP causes benign and malignant tumours at various organ sites
in rats and mice.

A very high oral dose of TCEP caused some inhibition of plasma
cholinesterase and brain neuropathy target esterase in hens, but did
not cause delayed neurotoxicity. In rats, a high dose of TCEP caused
convulsions, brain lesions and impaired performance in a water maze.

The LC₅₀/EC₅₀ values for organisms in the environment range from
90 to 5000 mg/litre.

A2. IDENTITY, PHYSICAL AND CHEMICAL PROPERTIES, AND ANALYTICAL METHODS

A2.1 Identity

Chemical formula: C₆H₁₂Cl₃O₄P

Chemical structure:

Relative molecular mass: 285.49

CAS name: tris(2-chloroethyl) phosphate

CAS registry number: 115-96-8

IUPAC name: phosphoric acid, tris(2-chloroethyl) ester

Synonyms: phosphoric acid, tris(2-chloroethyl) ester;
tris(beta chloroethyl) phosphate;
tris(chloroethyl) phosphate;
tris(2-chloroethyl) phosphate;
tris(2-chloroethyl) orthophosphate;
2-chloroethanol phosphate (3:1); ethanol,
2-chlorophosphate (3:1)

Trade names: Celanese Celluflex CEF; Celluflex CEF;
Disflamoll TCA; Fyrol CEF; Fyrol CF; Genomoll
P; Niax 3CF; Niax Flame retardant 3
(nospaa)CF; Hosta flam UP 810; Amgard TCEP;
Tolgard TCEP; Antiblaze TCEP; Levagard EP;
Nuogard TCEP

Common name: TCEP

A2.2 Physical and chemical properties

TCEP is a clear, colourless to pale yellow liquid with a slight
odour.

Boiling point: 351°C (at 760 mmHg)

Specific gravity: 1.425 at 20°C

Solubility: slightly soluble in water (8 g/litre at
20°C); soluble in aliphatic hydrocarbons,
polar organic solvents such as alcohols,
esters, ketones, and in aromatic hydrocarbons
and chlorinated hydrocarbons

Vapour pressure: < 10 mmHg at 25°C

Flash point: 202°C (Pensky Martin closed cup)

Stability: Rapid decomposition occurs above 220°C;
stable to short-term exposure at 150°C.
The products of thermal decomposition are
carbon monoxide, hydrogen chloride,
2-chloroethane and dichloroethane.
Hydrolytic stability decreases with
increasing temperature and pressure or
extreme pH.

Refractive index: 1.4721 at 20°C

Viscosity: 34 cP at 25°C

Henry's law constant: 3.29 × 10^-6

n-Octanol/water
partition coefficient
(log P_ow): 1.7

A2.3 Conversion factors

1 mg/m³ = 11.68 ppm
1 ppm = 0.0856 mg/m³

A2.4 Analytical methods

Selected methods for the analysis of TCEP are presented in Table
7.

Table 7. Methods for the analysis of tris(2-chloroethyl) phosphate

Sample matrix Sample preparation Assay procedure^a Limit of References
detection

Air Sample on glass-fibre filter GC/NPD 0.04-0.1 ng Haraguchi et al. (1985)
or XAD-7 resin;
prefractionate on
silica gel column

Water Extract with dichloromethane; GC/MS 10 ng/litre Ishikawa et al. (1985a);
dry (anhydrous sodium sulfate); Ishikawa & Baba (1988)
concentrate

Extract with dichloromethane GC/FPD 2 ng/litre Burchill et al. (1983)

Drinking-water Adsorb on XAD resin cartridge; GC/NPD 0.3 ng/litre^b LeBel et al. (1981)
extract with dichloromethane;
dry (anhydrous sodium sulfate);
concentrate

Adsorb on XAD resin cartridge; GC/MS and GC/NPD 0.1 ng/litre LeBel et al. (1987)
elute with acetone/ hexane; dry
(anhydrous sodium sulfate);
concentrate; extract (dichloromethane)

Sediment Extract with acetone; filter; add GC/MS 5 ng/g Ishikawa et al. (1985a)
filtrate to purified water, extract
with dichloromethane; dry (anhydrous
sodium sulfate); concentrate

Table 7. Methods for the analysis of tris(2-chloroethyl) phosphate

Sample matrix Sample preparation Assay procedure^a Limit of References
detection

Seawater, fish,
sea sediment Extract with acetonitrile and GC/MS 1-5 ng/g Kenmotsu et al. (1980b)
dichloromethane; adsorb; extract
on activated charcoal column; (fish)
extract with sulfuric acid; wash
with sodium hydroxide; purify by
Florisil chromatography GC/FPD

^a GC/NPD = gas chromatography/nitrogen phosphorus detection;
GC/MS = gas chromatography/ mass spectrometry;
GC/FPD = gas chromatography/flame photometric detection.

^b By direct fortification, in the concentration range of 1 up to 100 ng/litre, a recovery of 90% was obtained.

A3. SOURCES OF HUMAN AND ENVIRONMENTAL EXPOSURE

A3.1 Natural occurrence

TCEP is not a natural product.

A3.2 Anthropogenic sources

A3.2.1 Production and processes

TCEP production and use has been in rapid decline since the 1980s
as its historic use in rigid and flexible polyurethane foams and
systems has been substituted by other flame retardants.

Global TCEP consumption peaked at over 9000 tonnes in 1989 but
had declined to below 4000 tonnes by 1997.

All commercial TCEP has been produced by the reaction of
phosphorus oxychloride with ethylene oxide followed by subsequent
purification (personal communication by EFRA to IPCS, 1998).

A3.2.2 Uses

Historically TCEP was used in polyurethane foams and systems,
mainly for rigid foam but with minor use in flexible polyurethane.

TCEP is currently mainly used in the production of liquid
unsaturated polyester resins. It is also used in textile back-coating
formulations, PVC compounds, cellulose ester compounds and coatings.

TCEP is not recommended by producers for use as a flame retardant
additive for use in textiles nor for use in block polyurethane foams
because of the probability of its decomposition (personal
communication by EFRA to IPCS, 1998).

A4. ENVIRONMENTAL TRANSPORT, DISTRIBUTION AND TRANSFORMATION

A4.1 Transport and distrib